Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role

Purpose: This prospective study evaluated the prognostic significance of 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake in primary non-small cell lung cancer (NSCLC) at positron emission tomography, in a carefully staged population, while correcting for partial volume effects. Experimental Design: Two h...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2007-06, Vol.13 (11), p.3255-3263
Main Authors: Vesselle, Hubert, Freeman, Joseph D, Wiens, Linda, Stern, Joshua, Nguyen, Huang Q, Hawes, Stephen E, Bastian, Philip, Salskov, Alexander, Vallières, Eric, Wood, Douglas E
Format: Article
Language:English
Subjects:
Aged
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Disease-Free Survival
FDG
Female
Fluorodeoxyglucose F18 - pharmacokinetics
Humans
lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Male
Middle Aged
Molecular diagnosis and prognosis
partial volume
PET scans
positron emission tomography
Positron-Emission Tomography - methods
prognosis
Proportional Hazards Models
Prospective Studies
Radiopharmaceuticals - pharmacokinetics
Tomography, X-Ray Computed - methods
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: This prospective study evaluated the prognostic significance of 18 F-fluorodeoxyglucose ( 18 F-FDG) uptake in primary non-small cell lung cancer (NSCLC) at positron emission tomography, in a carefully staged population, while correcting for partial volume effects. Experimental Design: Two hundred eight potentially resectable NSCLC patients were referred for FDG positron emission tomography staging after thoracic computed tomography. Each tumor stage was confirmed surgically, or for some stage IV tumors by additional imaging. The tumor maximum pixel-standardized uptake value (maxSUV) and the maxSUV partial volume corrected for lesion size (PVCmaxSUV) were compared with overall survival and disease-free survival using Cox proportional hazards regression. Results: Stage distribution: stage I, 36%; stage II, 15%; stage III, 30%; stage IV, 19%. Patients were followed for a median of 33.6 months, with 90 deaths from NSCLC (median survival for all stages, 43.3 months). With respect to overall survival, the most significant cutoff value for both maxSUV and PVCmaxSUV was 7. MaxSUV ≥7 was significantly associated with an increased risk of death from NSCLC in univariable analysis, whereas PVCmaxSUV ≥7 was only marginally associated. However, in multivariable analyses, neither maxSUV ≥7 nor PVCmaxSUV ≥7 provided significant additional prognostic information over stage, tumor size, and age. In the 103 patients who underwent surgical resection only, surgical stage, but not maxSUV or PVCmaxSUV, was univariably associated with survival or recurrence. SUV definitions based on lean body mass, body surface area, and plasma glucose correction yielded identical results. Conclusions: As expected, tumor stage is prognostic in NSCLC. However, tumor FDG uptake does not provide additional prognostic information. This prospective study contradicts prior reports.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-06-1128